TY - JOUR
T1 - Deciphering the mechanism of action of antitubercular compounds with metabolomics
AU - Sakallioglu, Isin T.
AU - Barletta, Raúl G.
AU - Dussault, Patrick H.
AU - Powers, Robert
N1 - Funding Information:
This work was supported in part by funding from the National Science Foundation under Grant Number 1660921, the Redox Biology Center (P30 GM103335, NIGMS), the Nebraska Center for Integrated Biomolecular Communication (P20 GM113126, NIGMS), and the Nebraska Agricultural Experiment Station with funding from the USDA National Institute of Food and Agriculture (NEB-39-179 and NEB-39-178), the School of Veterinary Medicine and Biomedical Sciences, and the University of Nebraska-Lincoln College of Arts and Sciences.
Publisher Copyright:
© 2021 The Author(s)
PY - 2021/1
Y1 - 2021/1
N2 - Tuberculosis (TB), one of the oldest and deadliest bacterial diseases, continues to cause serious global economic, health, and social problems. Current TB treatments are lengthy, expensive, and routinely ineffective against emerging drug resistant strains. Thus, there is an urgent need for the identification and development of novel TB drugs possessing comprehensive and specific mechanisms of action (MoAs). Metabolomics is a valuable approach to elucidating the MoA, toxicity, and potency of promising chemical leads, which is a critical step of the drug discovery process. Recent advances in metabolomics methodologies for deciphering MoAs include high-throughput screening techniques, the integration of multiple omics methods, mass spectrometry imaging, and software for automated analysis. This review describes recently introduced metabolomics methodologies and techniques for drug discovery, highlighting specific applications to the discovery of new antitubercular drugs and the elucidation of their MoAs.
AB - Tuberculosis (TB), one of the oldest and deadliest bacterial diseases, continues to cause serious global economic, health, and social problems. Current TB treatments are lengthy, expensive, and routinely ineffective against emerging drug resistant strains. Thus, there is an urgent need for the identification and development of novel TB drugs possessing comprehensive and specific mechanisms of action (MoAs). Metabolomics is a valuable approach to elucidating the MoA, toxicity, and potency of promising chemical leads, which is a critical step of the drug discovery process. Recent advances in metabolomics methodologies for deciphering MoAs include high-throughput screening techniques, the integration of multiple omics methods, mass spectrometry imaging, and software for automated analysis. This review describes recently introduced metabolomics methodologies and techniques for drug discovery, highlighting specific applications to the discovery of new antitubercular drugs and the elucidation of their MoAs.
KW - Antitubercular drugs
KW - Drug discovery
KW - Mechanisms of action
KW - Metabolomics
KW - Multi-drug resistant tuberculosis
KW - Pharmacometabolomics
KW - Tuberculosis
UR - http://www.scopus.com/inward/record.url?scp=85112666015&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85112666015&partnerID=8YFLogxK
U2 - 10.1016/j.csbj.2021.07.034
DO - 10.1016/j.csbj.2021.07.034
M3 - Review article
C2 - 34429848
AN - SCOPUS:85112666015
SN - 2001-0370
VL - 19
SP - 4284
EP - 4299
JO - Computational and Structural Biotechnology Journal
JF - Computational and Structural Biotechnology Journal
ER -